Cencora, Inc. (COR)

Quarterly Report Filed: 2026-05-06

Key Insights

Filing dated 2026-05-06 for Q2 fiscal 2026 (ended 2026-03-31) indicates Cencora continues operating across two primary segments: US Healthcare Solutions and International Healthcare Solutions, suggesting sustained diversification in healthcare distribution.
Recent acquisitions including OneOncology (February 2026) and Retina Consultants of America (January 2025) demonstrate active M&A strategy to expand specialized healthcare service capabilities and market reach.
Presence of contingent consideration arrangements tied to business objectives for recent acquisitions indicates performance-based earnout structures, which could impact future earnings depending on achievement of specified milestones.
The filing structure shows multiple debt instruments outstanding (2.875% Senior Notes due 2028 and 3.625% Senior Notes due 2032), suggesting the company is managing debt obligations while funding growth initiatives through acquisitions.

Current Report Filed: 2026-05-06

Key Insights

Cencora announced Q3 fiscal 2026 earnings (quarter ended March 31, 2026) via news release, indicating the company continues regular quarterly reporting and financial disclosure obligations.
The company maintains investment-grade debt with two active senior note tranches (2.875% due 2028 and 3.625% due 2032), both trading on NYSE, reflecting stable long-term financing structure.
A conference call and webcast were scheduled for 8:30 a.m. ET on May 6, 2026, with presentation slides available on investor.cencora.com, providing stakeholders access to management commentary on quarterly performance and forward-looking guidance.

Insider Trading Filed: 2026-05-05

Key Insights

Director Lauren M. Tyler acquired 99 shares of Cencora common stock on 05/01/2026 at $304 per share as part of restricted stock units received in lieu of a $30,000 quarterly cash retainer, representing routine director compensation rather than discretionary insider buying.
The transaction reflects Cencora's non-employee director compensation structure using equity grants instead of cash, aligning director interests with shareholders but this is a standard practice with minimal significance for stock price movement.
Tyler's total beneficial ownership following the transaction stands at 3,809 shares in direct form, indicating a relatively modest stake for a board member and suggesting limited concentrated insider confidence in the stock.

Insider Trading Filed: 2026-05-05

Key Insights

Ellen G. Cooper, a Director at Cencora, acquired 99 restricted stock units (RSUs) valued at approximately $30,000 on May 1, 2026, representing her quarterly non-employee director retainer payment.
The RSUs were granted in lieu of cash compensation, with vesting deferred until Cooper's cessation of service, indicating standard director compensation practices with retention incentives.
This routine director compensation transaction shows no insider selling activity and reflects normal board compensation governance, with total beneficial ownership now at 796 shares directly held.
The filing demonstrates stable board composition and director commitment to the company, as insiders are accepting equity compensation rather than opting for cash alternatives.

Insider Trading Filed: 2026-05-05

Key Insights

Director Dennis M. Nally acquired 116 shares of COR common stock on 05/01/2026 at $304/share, with total beneficial ownership reaching 13,075 shares, indicating continued confidence in the company by board leadership.
The acquisition was structured as compensation through Cencora's Non-Employee Director Compensation Program (quarterly $35,000 cash retainer issued as stock), representing routine board compensation rather than discretionary open-market insider buying.
This transaction reflects standard director equity participation practices and does not signal any material strategic insight about company prospects, as the shares were issued in lieu of standard cash compensation.

Current Report Filed: 2026-03-06

Key Insights

Cencora, Inc. (COR) held its 2026 Annual Meeting of Shareholders on March 5, 2026, where shareholders voted on the election of directors, the fiscal 2025 compensation of the company's named executive officers, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal 2026.
The election of the eleven directors nominated by the company was approved by the shareholders, with the majority of votes cast in favor of each nominee.
The shareholders approved, on an advisory basis, the fiscal 2025 compensation of the company's named executive officers, and also ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal 2026.

Insider Trading Filed: 2026-02-24

Key Insights

Robert P. Mauch, President & CEO of Cencora, Inc. (COR), exercised 3,762 stock options and immediately sold the same amount of shares, indicating he is monetizing a portion of his equity holdings.
The exercise price of the stock options was $86.09, while the sale price was $358.94, suggesting Mauch is profiting significantly from the transaction.
Mauch's total direct ownership in Cencora has decreased from 69,155 shares to 65,393 shares following this transaction.

Current Report Filed: 2026-02-18

Key Insights

Cencora, Inc. has agreed to merge its animal health business MWI with Covetrus, Inc. for an enterprise value of $3.5 billion, which will provide the company with significant cash and equity consideration.
The transaction is subject to regulatory approvals and is expected to close, at which point Cencora will hold a 34.3% ownership stake in the combined entity.
The merger with Covetrus represents a strategic shift for Cencora as it focuses on its core business and unlocks value from the MWI division.

Current Report Filed: 2026-02-13

Key Insights

Cencora, Inc. completed a $3 billion bond offering with various maturities and coupon rates, signaling their need for additional capital.
The company issued new senior notes across a range of maturities from 2029 to 2056, indicating potential long-term growth plans or refinancing needs.
The bond offering provides Cencora with enhanced financial flexibility, but the high coupon rates may impact their future profitability and cash flow.

Current Report Filed: 2026-02-11

Key Insights

Cencora, Inc. issued $3 billion in new senior notes across maturities from 2029 to 2056, indicating the company is taking advantage of favorable market conditions to refinance existing debt.
The net proceeds from the note offering will be used to repay the company's $3 billion 364-Day Term Loan Facility, reducing interest expense and extending the debt maturity profile.
Several of the underwriters for this note offering have long-standing relationships with Cencora, having served as underwriters for past note issuances and in various roles for the company's credit facilities.

Current Report Filed: 2026-02-10

Key Insights

Cencora, Inc. has acquired Retina Consultants of America (RCA), a strategic move that may expand its medical services offerings.
The company has issued $5,000 million in senior notes due in 2028 and 2032, potentially indicating plans for future growth and expansion.
The company's customer concentration risk is notable, with two major customers (Walgreens and Evernorth Health Services) accounting for a significant portion of sales and accounts receivable.

Quarterly Report Filed: 2026-02-04

Key Insights

The company acquired Retina Consultants of America (RCA) on January 2, 2025, which expanded its healthcare solutions segment and added intangible assets like trade names and customer relationships.
Cencora reported a 5% year-over-year increase in revenue for Q4 2025, driven by growth in both its US and international healthcare solutions segments.
The company has a diversified debt structure with a mix of senior notes, term loans, and credit facilities, which provides financial flexibility.

Current Report Filed: 2026-02-04

Key Insights

Cencora, Inc. announced the acquisition of a majority stake in OneOncology, a physician-led national platform focused on oncology, for $4.6 billion. This strategic move will expand Cencora's presence in the U.S. healthcare solutions segment.
The company reported its Q4 2025 earnings, providing an update on its financial performance for the quarter. Investors will be interested in analyzing the earnings results and any guidance provided for the upcoming fiscal year.
Cencora has issued new debt financing to fund the OneOncology acquisition, which could impact the company's leverage and capital structure going forward.

Insider Trading Filed: 2026-01-22

Key Insights

Robert P. Mauch, the President and CEO of Cencora, Inc. (COR), exercised 3,763 non-qualified stock options and sold 5,096 shares of the company's common stock on January 20, 2026.
Mauch's sale of shares following the exercise of options suggests he is taking some profits, but he still maintains a substantial direct ownership stake of 66,726 shares.
The transaction was executed pursuant to a pre-arranged 10b5-1 trading plan, indicating it was part of a structured liquidity program rather than a reaction to new information.

Current Report Filed: 2026-01-22

Key Insights

Cencora, Inc. appointed a new director, Ellen G. Cooper, to its Board of Directors, expanding the board from 10 to 11 members.
The company issued new 2.875% senior notes due 2028 and 3.625% senior notes due 2032, which will be traded on the New York Stock Exchange.
There are no indications of any family relationships between the new director and the company's executives, or any related party transactions requiring disclosure.

Current Report Filed: 2026-01-16

Key Insights

Cencora, Inc. increased the aggregate amount of commitments under its Revolving Credit Agreement by $1.0 billion to $5.5 billion, providing additional financial flexibility.
The company entered into a $1.5 billion Term Credit Agreement and a $3.0 billion 364-Day Term Credit Facility to fund the acquisition of the majority stake in OneOncology, indicating its strategic focus on growing its oncology business.
The new credit facilities include financial covenants and terms similar to the company's existing Revolving Credit Agreement, suggesting a continuity in its debt management approach.

Insider Trading Filed: 2026-01-07

Key Insights

Silvana Battaglia, the Executive Vice President of Cencora, Inc. (COR), acquired 27.344 shares of the company's common stock through the Employee Stock Purchase Plan on 12/31/2025.
The acquisition of shares by Battaglia is a positive sign as it indicates the executive's confidence in the company's prospects and aligns their interests with those of shareholders.
The amount of shares acquired is relatively small, suggesting the transaction is more symbolic than a significant investment, but it still signals a vote of confidence from a key insider.

Insider Trading Filed: 2026-01-07

Key Insights

Elizabeth S. Campbell, the Executive Vice President, acquired 33.526 shares of Cencora, Inc. common stock through the Employee Stock Purchase Plan on 12/31/2025.
This insider purchase indicates that the Executive Vice President has confidence in the company's future performance and is willing to invest further in Cencora, Inc. shares.
The transaction was executed pursuant to a Rule 10b5-1 trading plan, suggesting a structured approach to insider trading that complies with securities regulations.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information